Scholarlink

Background <p>Low-temperature hemodialysis (<i>cool dialysis</i>) is a therapeutic strategy aimed at preventing intradialytic hypotension and improving hemodynamic stability in patients with end-stage kidney disease (ESKD). Over the past decade, several studies have investigated its potential impact on cardiovascular outcomes, neurological protection, and clinical tolerability, with sometimes conflicting results.</p> Methods <p>An overview of the literature was conducted using PubMed® from January 1, 2015 to July 31, 2025, with the search terms <i>cooler dialysis</i>, <i>cooler dialysate</i>, and <i>cooler dialysate and hemodynamic stability</i>. Randomized and prospective clinical studies assessing the effects of low-temperature hemodialysis on hemodynamic, cardiac, and neurological outcomes were included.</p> Results <p>Nine studies met the inclusion criteria. Small-scale trials reported a significant reduction in intradialytic hypotension episodes and a protective effect on left ventricular function. The large multicenter MyTEMP trial, while showing no significant reduction in major cardiovascular events, confirmed a trend toward improved blood pressure stability, at the expense of increased thermal discomfort. A Bayesian reanalysis of MyTEMP data suggested a high probability of clinical benefit. Effects on cerebral microcirculation and cognitive function remain uncertain.</p> Conclusions <p>Low-temperature hemodialysis is associated with improved hemodynamic stability and potential myocardial protection in specific patient subgroups; however, consistent effects on major cardiovascular events or cognitive decline in the general population have not been observed. Large, multicenter studies with extended follow-up are needed to better define clinical indications, long-term outcomes, and the identification of “responder” patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Does low-temperature dialysis still represent an advantage?: a narrative review from the last decade

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Lorenzo D’Elia,
  • Deborah Di Vico,
  • Giovanni Otranto,
  • Annalisa Villani,
  • Luca Di Lullo,
  • Antonio Bellasi,
  • Vincenzo Barbera

摘要

Background

Low-temperature hemodialysis (cool dialysis) is a therapeutic strategy aimed at preventing intradialytic hypotension and improving hemodynamic stability in patients with end-stage kidney disease (ESKD). Over the past decade, several studies have investigated its potential impact on cardiovascular outcomes, neurological protection, and clinical tolerability, with sometimes conflicting results.

Methods

An overview of the literature was conducted using PubMed® from January 1, 2015 to July 31, 2025, with the search terms cooler dialysis, cooler dialysate, and cooler dialysate and hemodynamic stability. Randomized and prospective clinical studies assessing the effects of low-temperature hemodialysis on hemodynamic, cardiac, and neurological outcomes were included.

Results

Nine studies met the inclusion criteria. Small-scale trials reported a significant reduction in intradialytic hypotension episodes and a protective effect on left ventricular function. The large multicenter MyTEMP trial, while showing no significant reduction in major cardiovascular events, confirmed a trend toward improved blood pressure stability, at the expense of increased thermal discomfort. A Bayesian reanalysis of MyTEMP data suggested a high probability of clinical benefit. Effects on cerebral microcirculation and cognitive function remain uncertain.

Conclusions

Low-temperature hemodialysis is associated with improved hemodynamic stability and potential myocardial protection in specific patient subgroups; however, consistent effects on major cardiovascular events or cognitive decline in the general population have not been observed. Large, multicenter studies with extended follow-up are needed to better define clinical indications, long-term outcomes, and the identification of “responder” patients.